Anaplastic astrocytoma in adults

Roger Stupp*, Michele Reni, Gemma Gatta, Elena Mazza, Charles Vecht

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

54 Scopus citations


Anaplastic astrocytoma is an uncommon disease in the adult population. Prognosis is influenced by age, symptom duration, mental status and Karnofsky performance status. A truly complete resection, which is a recognized independent prognostic factor, is not possible and recurrence in the surgical cavity is common. Based on randomized data available, chemotherapy has consistently failed to improve the outcome of patients with anaplastic astrocytoma, while a meta-analysis showed a small, but significant improvement in survival favouring the use of chemotherapy. Outside a clinical trial, postoperative radiotherapy (30 × 2 Gy) remains the standard adjuvant therapy for most patients. For elderly patients, the application of treatment is usually based on performance status and neurological function. In recurrent disease, chemotherapy with temozolomide has been proven to be active and well-tolerated in phase II trials, but no comparative phase III trials of other cytotoxic drugs have been conducted.

Original languageEnglish (US)
Pages (from-to)72-80
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Issue number1
StatePublished - Jul 1 2007


  • Anaplastic astrocytoma
  • Chemotherapy
  • Cytotoxic drugs

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'Anaplastic astrocytoma in adults'. Together they form a unique fingerprint.

Cite this